Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com

Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

By AJMC Contributor

July 31st 2025

A cumulative review offers strong evidence that acalabrutinib has a low incidence of cardiac failure in both clinical trial and real-world settings.

Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com

Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

By Jared Kaltwasser

July 29th 2025

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.

Older regimens for CLL were frequently used in older patients and were associated with significantly shorter overall survival, the authors found. | image credit: Saiful52 - stock.adobe.com

Newer Agents Should Be Used in First Line for Older Patients With CLL

By AJMC Contributor

July 28th 2025

New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.

Despite the benefits associated with adequate physical function in CLL, 70% of respondents said they had never received any physical activity advice from a doctor. | Image Credit: kieferpix - stock.adobe.com.jpg

Exercise Tied to Improved Symptoms, QOL in Patients With CLL

By AJMC Contributor

July 27th 2025

While physical activity was linked with improved quality of life (QOL), the majority of patients are not given the recommendation from their doctor.

<1 2 3 4 5 6

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions